This statistic displays the percentage of adults who self-reported having a cardiovascular disease that use medication in selected countries as of 2018. As of that year, 17 percent of the adult population suffering from cardiovascular conditions in China used prescription medication only.

Global Cardiovascular System Medicine Use by Country, 2023 Discover more data with ReportLinker!

In 2021, it was estimated that the Pacific island country Nauru had the highest death rate from cardiovascular disease in the world, with around 694 deaths per 100,000 population. In 2021, ischemic heart disease was the leading cause of death worldwide, resulting in over nine million deaths.

The Europe Digital Health For Cardiovascular Market would witness market growth of 21.7% CAGR during the forecast period (2024-2031). The Germany market dominated the Europe Digital Health For Cardiovascular Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, a

In 2022, South Korea had the lowest rate of death from ischemic heart disease among OECD countries, with around ** deaths per 100,000 inhabitants. In comparison, there were around *** deaths due to ischemic heart disease per 100,000 population in Lithuania. Cardiovascular disease worldwide Fatty deposits accumulating in the inner wall of the coronary artery that restrict blood flow to the heart cause ischemic heart disease (IHD) and can also precipitate heart attacks and strokes. Cardiovascular risk factors such as smoking, heavy alcohol use, and an unhealthy diet are more prevalent in Eastern European countries, contributing to a much higher burden of cardiovascular diseases and deaths. Prevention and intervention Invasive interventions for heart disease can include surgical procedures such as heart bypass surgery- where blood is diverted around clogged parts of major arteries. Other medical interventions include the use of prescribed or over-the-counter drugs, such as prescription nitrates or beta blockers, or OTC medications like aspirin. Lifestyle factors to lower blood pressure and cholesterol levels can help decrease the risk of heart attacks and other cardiovascular diseases, including maintaining a healthy diet, regular physical activity, and smoking and alcohol cessation.

The Latin America, Middle East and Africa Digital Health For Cardiovascular Market would witness market growth of 23.9% CAGR during the forecast period (2024-2031). The Brazil market dominated the LAMEA Digital Health For Cardiovascular Market by Country in 2023, and would continue to be a dominan

The Asia Pacific Digital Health For Cardiovascular Market would witness market growth of 22.6% CAGR during the forecast period (2024-2031). The China market dominated the Asia Pacific Digital Health For Cardiovascular Market by Country in 2023, and would continue to be a dominant market till 2031;

The North America Digital Health For Cardiovascular Market would witness market growth of 21.3% CAGR during the forecast period (2024-2031). The US market dominated the North America Digital Health For Cardiovascular Market by Country in 2023, and would continue to be a dominant market till 2031;

This statistic displays the mortality rate from cardiovascular disease in the United Kingdom in 2023, by country. In that year, Scotland had the highest death rate from the disease, with *** deaths per 100,000 population.

Replication code for "Use of Statins for the Prevention of Cardiovascular Disease in 41 Low- and Middle-Income Countries: A Cross-Sectional Study of Nationally Representative, Individual-Level Data"

BackgroundThe environment in which people live is known to be important in influencing diet, physical activity, smoking, psychosocial and other risk factors for cardiovascular (CV) disease. However no instrument exists that evaluates communities for these multiple environmental factors and is suitable for use across different communities, regions and countries. This report describes the design and reliability of an instrument to measure environmental determinants of CV risk factors.Method/Principal FindingsThe Environmental Profile of Community Health (EPOCH) instrument comprises two parts: (I) an assessment of the physical environment, and (II) an interviewer-administered questionnaire to collect residents' perceptions of their community. We examined the inter-rater reliability amongst 3 observers from each region of the direct observation component of the instrument (EPOCH I) in 93 rural and urban communities in 5 countries (Canada, Colombia, Brazil, China and India). Data collection using the EPOCH instrument was feasible in all communities. Reliability of the instrument was excellent (Intraclass Correlation Coefficient - ICC>0.75) for 24 of 38 items and fair to good (ICC 0.4–0.75) for 14 of 38 items.ConclusionThis report shows data collection with the EPOCH instrument is feasible and direct observation of community measures reliable. The EPOCH instrument will enable further research on environmental determinants of health for population studies from a broad range of settings.

The European Health Interview Survey (EHIS) aims at measuring on a harmonised basis and with a high degree of comparability among Member States (MS) the health status (including disability), health determinants (lifestyle) of the EU citizens and use of health care services and limitations in accessing it.

The general coverage of the survey is the population aged 15 or over living in private households residing in the territory of the country.

EHIS was developed between 2003 and 2006. It consists of four modules on health status, health determinants, health care, and background variables (socio-demographic characteristics of the population).

Three waves of EHIS have currently been implemented. The first wave of EHIS (EHIS wave 1 or EHIS round 2008) was conducted between 2006 and 2009 in 17 EU Member States as well as Switzerland and Turkey.

The second wave (EHIS wave 2 or EHIS round 2014) was conducted between 2013 and 2015 in all EU Member States, Iceland, Norway and Turkey according to the Commission Regulation 141/2013.

The third wave of EHIS was conducted in 2019. All Member States participated in the EHIS wave 3 in accordance with the Commission Regulation (EU) No. 2018/255. A derogation regarding the data collection period was granted for some countries: the data collection period was 2018 for Belgium, 2018-2020 for Austria and Germany, and 2019-2020 for Malta.

The questionnaire consists of the same four modules for all the EHIS waves and over the years, some changes to the questionnaire have been implemented to satisfy specific users’ needs. Also, countries are allowed to include additional questions in the specific submodules or even specific sub-modules in the survey if this does not have an impact on the results of the compulsory variable

EHIS includes the following topics:

Health status
This topic includes different dimensions of health status and health-related activity limitations:

• General health status (Minimum European health module): self-perceived health, chronic morbidity and disability (activity limitation)
• Disease-specific morbidity
• Accidents and injuries
• Health-related absenteeism from work
• Physical and sensory functional limitations (also cognitive limitations in wave 3)
• Difficulties in personal care activities / activities of daily living (such as eating and washing) and help received/needed
• Household activities / Instrumental activities of daily living (such as preparing meals and shopping) and help received/needed
• Pain
• Aspect of mental health (psychological distress and mental well-being in the first wave, depressive symptoms in the second and third waves)
• Work-related health problems (only in the first wave).

Health care
This topic covers the use of different types of medicines and formal and informal health and social care services, which are complemented by data on health-related expenditure, and limitations in access to and satisfaction with health care services:

• Hospitalisation (in-patient and day care)
• Consultations with doctors and dentists
• Visits to specific health professionals (such as physiotherapists or psychologists)
• Use of home care services
• Use of medicines (prescribed and non-prescribed)
• Healthcare preventive actions (such as influenza vaccination, breast examination, cervical smear test and blood tests)
• Unmet needs for health care
• Out-of-pocket payments for medical care (only in the first wave)
• Satisfaction with services provided by healthcare providers (only in the first wave)
• Visits to specific categories of alternative medicine practitioners (only in the first wave).

Health determinants
This topic includes various individual and environmental health determinants:

• Height and weight
• Physical activity/exercise
• Consumption of fruits, vegetables and juice
• Drinking sugar-sweetened soft drinks (only in the third wave)
• Tobacco smoking behaviour and exposure to tobacco smoke
• Use of e-cigarettes or similar electronic devices (only in the third wave)
• Alcohol consumption
• Social support
• Provision of informal care or assistance (only in the second and third waves)
• Illicit drug use (only in the first wave)
• Environment (home and workplace exposures, criminality exposure) (only in the first wave).

Background variables on demography and socio-economic characteristics.

All indicators are expressed as percentages within the population and statistics are broken down by age and sex and one other dimension such as educational attainment level, income quintile group, degree of urbanization, country of birth, country of citizenship, level of disability (activity limitation).

This repository contains the R scripts and country-level panel dataset used for all analyses in the manuscript entitled "Could Plant-Based Protein and Fiber Be the Key to Combating Cardiovascular Diseases? An Assessment of Developed and Developing OECD Countries". The code enables full replication of all data processing, statistical analyses (including PCA, clustering, time series forecasting, and dynamic panel regression), and the generation of all figures and tables reported in the article. The dataset was compiled from publicly available sources as described in the manuscript.

The R scripts and data files provided in this repository are made available exclusively for the purposes of peer review, reproducibility, and validation of the analyses presented in the associated manuscript. Any use of these materials for new research projects, publications, derivative works, or for any other purpose beyond the scope of reviewing this manuscript is strictly prohibited without explicit written permission from the corresponding author. Unauthorized use, reproduction, or redistribution of the code or data for independent research, commercial purposes, or publication will be considered a violation of intellectual property rights and may result in legal action. By accessing these files, reviewers and editors acknowledge and accept these conditions. If you have any questions regarding appropriate use or would like to request permission for further use, please contact the corresponding author directly (salimyilmaz142@gmail.com).

Production Value: Other Drug: Home Use: Cardiovascular Preparation data was reported at 70,238.000 JPY th in Dec 2017. This records an increase from the previous number of 63,062.000 JPY th for Nov 2017. Production Value: Other Drug: Home Use: Cardiovascular Preparation data is updated monthly, averaging 87,335.000 JPY th from Jan 2006 (Median) to Dec 2017, with 144 observations. The data reached an all-time high of 155,378.000 JPY th in Jul 2007 and a record low of 29,188.000 JPY th in Apr 2017. Production Value: Other Drug: Home Use: Cardiovascular Preparation data remains active status in CEIC and is reported by Ministry of Health, Labour and Welfare. The data is categorized under Global Database’s Japan – Table JP.RT007: Production Value by Application and Therapeutic Category.

Japan Inventory Value: Month End: Other Drug: Home Use: Cardiovascular Preparation data was reported at 90,792.000 JPY th in Dec 2017. This records an increase from the previous number of 89,954.000 JPY th for Nov 2017. Japan Inventory Value: Month End: Other Drug: Home Use: Cardiovascular Preparation data is updated monthly, averaging 145,353.000 JPY th from Jan 2006 (Median) to Dec 2017, with 144 observations. The data reached an all-time high of 203,919.000 JPY th in Jul 2007 and a record low of 77,996.000 JPY th in Apr 2017. Japan Inventory Value: Month End: Other Drug: Home Use: Cardiovascular Preparation data remains active status in CEIC and is reported by Ministry of Health, Labour and Welfare. The data is categorized under Global Database’s Japan – Table JP.RT034: Inventory Value by Application and Therapeutic Category.

Cardiovascular OCT Imaging Market Outlook

In 2023, the global cardiovascular OCT imaging market size was valued at approximately USD 450 million, and it is poised to grow at a robust CAGR of 8.5% over the forecast period, reaching an estimated USD 900 million by 2032. This impressive growth is driven by various factors, including advancements in imaging technologies, the rising prevalence of cardiovascular diseases, and increasing awareness about the benefits of early diagnosis.

The key growth driver for the cardiovascular OCT imaging market is the increasing incidence of cardiovascular diseases worldwide. According to the World Health Organization, cardiovascular diseases are the leading cause of death globally, accounting for an estimated 17.9 million deaths each year. This alarming statistic underscores the urgent need for advanced diagnostic tools like OCT imaging that can provide high-resolution images and detailed information about the cardiovascular system. The ability of OCT imaging to offer real-time, precise visualizations aids in the accurate assessment and treatment of cardiovascular conditions, thus propelling its market growth.

Technological advancements in optical coherence tomography (OCT) are another significant factor contributing to market growth. Over the past few years, there have been substantial innovations in OCT imaging, including the development of higher resolution imaging, faster acquisition times, and improved software analytics. These technological enhancements make OCT imaging more effective and efficient, thereby increasing its adoption among healthcare providers. Additionally, the integration of artificial intelligence (AI) and machine learning (ML) into OCT systems is expected to further enhance diagnostic accuracy and patient outcomes, creating new growth opportunities for the market.

Furthermore, increasing healthcare expenditure and supportive government initiatives are boosting the adoption of cardiovascular OCT imaging. Governments and health organizations worldwide are investing heavily in advanced diagnostic technologies to improve patient care and outcomes. For instance, several countries have launched national screening programs for cardiovascular diseases, which include the use of advanced imaging technologies like OCT. These initiatives not only increase the accessibility of OCT imaging but also drive market demand by ensuring a steady influx of patients requiring diagnostic evaluations.

Regionally, North America dominates the cardiovascular OCT imaging market, accounting for the largest share due to its well-established healthcare infrastructure, high prevalence of cardiovascular diseases, and significant investments in healthcare technology. However, the Asia Pacific region is expected to witness the highest growth rate during the forecast period. The rising healthcare expenditure, improving healthcare infrastructure, and increasing awareness about early diagnosis and treatment of cardiovascular diseases in countries like China and India are driving the market growth in this region.

Product Type Analysis

The cardiovascular OCT imaging market, segmented by product type, encompasses catheters, consoles, and software. Catheters are essential components in OCT imaging as they are the primary tools used to access the cardiovascular system and capture high-resolution images. The increasing prevalence of cardiovascular diseases and the rising number of interventional cardiology procedures are driving the demand for advanced catheters. Additionally, innovations in catheter technology, such as the development of more flexible and smaller diameter catheters, enhance imaging capabilities and patient comfort, further fueling market growth.

Consoles, which serve as the central unit for processing and displaying OCT images, are another critical segment. The demand for advanced consoles is growing due to their ability to provide high-definition images and real-time data analysis. Innovations in console technology, including the integration of AI and ML, are enhancing diagnostic accuracy and efficiency. These advancements are making consoles indispensable in both clinical and research settings, thus contributing to the overall growth of the cardiovascular OCT imaging market.

Software plays a pivotal role in the OCT imaging process by facilitating image acquisition, processing, and analysis. The increasing adoption of advanced software solutions that offer enhanced image processing capabilities and user-friendly interfaces is driving the growth of this segment. Additionally, software advanceme

Abstract Background There are substantial opportunities to improve the quality of cardiovascular care in developing countries through the implementation of a quality program. Objective To evaluate the effect of a Best Practice in Cardiology (BPC) program on performance measures and patient outcomes related to heart failure, atrial fibrillation and acute coronary syndromes in a subset of Brazilian public hospitals. Methods The Boas Práticas em Cardiologia (BPC) program was adapted from the American Heart Association’s (AHA) Get With The Guidelines (GWTG) Program for use in Brazil. The program is being started simultaneously in three care domains (acute coronary syndrome, atrial fibrillation and heart failure), which is an approach that has never been tested within the GWTG. There are six axes of interventions borrowed from knowledge translation literature that will address local barriers identified through structured interviews and regular audit and feedback meetings. The intervention is planned to include at least 10 hospitals and 1,500 patients per heart condition. The primary endpoint includes the rates of overall adherence to care measures recommended by the guidelines. Secondary endpoints include the effect of the program on length of stay, overall and specific mortality, readmission rates, quality of life, patients’ health perception and patients’ adherence to prescribed interventions. Results It is expected that participating hospitals will improve and sustain their overall adherence rates to evidence-based recommendations and patient outcomes. This is the first such cardiovascular quality improvement (QI) program in South America and will provide important information on how successful programs from developed countries like the United States can be adapted to meet the needs of countries with developing economies like Brazil. Also, a successful program will give valuable information for the development of QI programs in other developing countries. Conclusions This real-world study provides information for assessing and increasing adherence to cardiology guidelines in Brazil, as well as improvements in care processes. (Arq Bras Cardiol. 2019; xx(x):xxx-xxx)

Weighted distribution of cardiovascular disease risk factors in participants aged 30–74 years from population-based surveys conducted in 45 low- and middle-income countries between 2005 and 2017.

According to Cognitive Market Research, the Cardiovascular Devices Market Size was USD XX Billion in 2024 and is set to achieve a market size of USD XX Billion by the end of 2033 growing at a CAGR of XX% from 2025 to 2033.

North America held largest share of XX% in the year 2024 
Europe held share of XX% in the year 2024 
Asia-Pacific held significant share of XX% in the year 2024 
South America held significant share of XX% in the year 2024
Middle East and Africa held significant share of XX% in the year 2024 

Market Dynamics of the Cardiovascular Devices Market

Key Drivers for the Cardiovascular Devices Market

Rising in cardiovascular diseases prevalence fuels the cardiovascular devices market

The cardiovascular disorders are the group of medical condition where it affects heart and blood vessels, encompassing various diseases and disorder that affects on the circulatory system. The cardiac devices help to maintain the regular heart function and blood flow in patients with weak improper function of heart. The global cardiac device market shows significant growth, largely driven by increase in prevalence of heart disease. The cardiovascular disease treatment is costly in terms of healthcare services. Now the conditions like coronary artery disease and heart failure are becoming increasingly prevalent, so there is increase in demand of coronary stents and crucial devices which are used to treat the cardiovascular diseases. Also, the global population increases and continues to age the incidence of chronic heart condition is expected to rise. This demographic condition is shift further and results in growing need of cardiovascular devices that can treat the wide range of heart diseases.

For instance, according to centers for disease control and prevention (CDC) in the United States heart diseases is the major cause of death for both men and women and people of most racial and ethnic groups. They said that one person dies every 33 seconds from cardiovascular disease. In 2022, 702,880 people died from heart disease. That is equivalent to 1 in every 5 deaths

(Source -https://www.cdc.gov/heart-disease/index.html)

Thus, due to the rising patients in cardiovascular disease segment and the advancement in technology boosts the cardiovascular devices market. Rising awareness of health also helps to drive this market.

The rise in healthcare expenditure drives the Cardiovascular Devices Market

Globally the health awareness is increasing vastly countries monitor their health of the population related to cardiac health preferably. They also focus on the expansion of healthcare expenditure where the people also now get aware about their health. The advancement in technology of medical devices increases the patient convenience and now they can get treatment and monitor their health more effectively. Each country now spends on their healthcare expenditure to provide healthcare service to all needy people who cannot afford the costly devices. For instance, U.S. health expenditure grew by 4.1% in 2022 to $4.5 trillion or $13,493 per capita. This rate of growth is similar to pre-pandemic levels (4.1% in 2019). While government expenditure to contain the pandemic resulted in significant growth in NHE, these expenditures fell sharply in 2021 while use of medical goods and services recovered. By 2022, overall trends in health expenditure more closely approximated that of the pre-pandemic era.

(Source - https://www.ama-assn.org/about/research/trends-health-care-spending)

The market for cardiovascular devices is expected to grow as a result of rising healthcare costs. The total amount spent on healthcare-related services, goods, and activities over a given time period usually at the individual, community, national, or international level is referred to as healthcare expenditures. Adoption of cutting-edge cardiovascular technologies and devices is made possible by increased healthcare spending, which improves patient outcomes and care. For Instance, in Europe the spending on cardiovascular disease is greater than the spending done in Germany. CVD is estimated to cost the EU €282 billion annually, with health and long-term care accounting for €155 billion (55%), equaling 11% of EU-health expenditure. Productivity losses accounted for 17% (€48 billion), whereas informal care costs were €79 billion (28%). CVD ...

Shipment Value: Other Drug: Home Use: Cardiovascular Preparation data was reported at 68,668.000 JPY th in Dec 2017. This records an increase from the previous number of 63,264.000 JPY th for Nov 2017. Shipment Value: Other Drug: Home Use: Cardiovascular Preparation data is updated monthly, averaging 88,711.000 JPY th from Jan 2006 (Median) to Dec 2017, with 144 observations. The data reached an all-time high of 172,541.000 JPY th in Dec 2008 and a record low of 33,009.000 JPY th in Aug 2013. Shipment Value: Other Drug: Home Use: Cardiovascular Preparation data remains active status in CEIC and is reported by Ministry of Health, Labour and Welfare. The data is categorized under Global Database’s Japan – Table JP.RT028: Shipment Value by Application and Therapeutic Category.